Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Lenalidomide (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions
- 26 Jan 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017.
- 12 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 12 May 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2016.